Olema Oncology

Olema Oncology is a cancer medicines company dedicated to impacting breast cancer and beyond. Our lead program, palazestrant (OP-1250), is a differentiated oral medicine known as a complete estrogen receptor antagonist (CERAN) initially in development for metastatic breast cancer. Our pipeline also includes OP-3136, a potent, selective oral inhibitor of the KAT6 pathway. At Olema, we are building a focused team committed to our mission with intention and clarity. Working alongside a talented, passionate group of leaders and advisors, we strive to create better medicines that aim to help patients feel better, longer. For more information, visit us at www.olema.com.

Karius

Karius sees a world where infectious disease is no longer a major threat to human health. The Karius Test uses genomics and AI to map a patient’s microbial landscape from a single blood sample to enable clinicians to make rapid treatment decisions.

Pliant Therapeutics

Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. At Pliant, we share a commitment and a clear passion to drive innovative science towards addressing areas of unmet medical need. Together we believe we have the power to make a difference in the lives of patients and those impacted by fibrotic diseases. We believe that by harnessing the therapeutic potential of integrin biology and TGF-β modulation, there is a potential to create drug candidates aimed at halting or even reversing fibrotic diseases. Pliant recognizes the importance of diversity, equity and inclusion initiatives and that they require an evolving and ongoing commitment. Pliant is an equal opportunity employer and does not discriminate against any individual or potential candidate based on race, color, religion, sex, national origin, sexual preference or any other legally protected category. Pliant is located in South San Francisco, California, the birthplace of biotechnology. Proud to be a San Francisco Business Times Best Place to Work in 2023. Learn more about how we are breaking ground in the treatment of fibrotic diseases at www.PliantRx.com.

MicroGenDX

MicroGenDX provides qPCR+NGS sequencing for the detection of infectious diseases. The American Medical Association (AMA) and Medicare have issued a billing code to MicroGenDX to provide this testing service, recognizing this technology as medically necessary. MicroGenDX is trusted by over 39,000 physicians worldwide and has helped over 900,000 patients with diagnostic testing for their chronic and life-threatening infections. MicroGenDX is a College of American Pathologists (CAP) accredited and Clinical Laboratory Improvements Amendments (CLIA) licensed clinical laboratory. Tens of thousands of patients with chronic and often life-threatening infections have benefited from MicroGenDX’s work. MicroGenDX's NGS technology offers several advantages over traditional culture-based methods for identifying microorganisms. It can detect a wider range of microorganisms, including those that are difficult to culture or grow in a laboratory. It also provides more accurate and comprehensive results, as it can detect multiple microorganisms in a single sample and identify them at the species or strain level. Additionally, NGS technology is faster than traditional methods, allowing for quicker diagnosis and treatment decisions.  MicroGenDX's testing services are used in a variety of settings, including hospitals, long-term care facilities, dental offices, and veterinary clinics. Their technology has been applied to a wide range of clinical conditions, including chronic wounds, orthopedic infections, respiratory infections, and urinary tract infections, among others.

Anima Biotech

Anima is a Tech.Bio company at the intersection of mRNA biology and AI. We are advancing the mRNA Lightning platform for the discovery of small molecule mRNA drugs and novel mRNA biology targets. Built from the ground up with over a decade of expertise in mRNA biology, the platform integrates mRNA biology with AI imaging technologies to visualize the entire life cycle of mRNA in cells and decode the mRNA biology underlying a disease. Utilizing millions of images from both healthy and diseased cells, we train disease-specific mRNA image analysis neural networks to recognize a disease signature, an mRNA biology pathway that underlies disease phenotype. Our tera-scale mRNA biology lab then conducts high content screening from our optimized library of mRNA modulators, sending the images to our mRNA image neural network to identify active compounds, the molecules that visually alter the mRNA biology signature. Our MOAi technology, the mRNA biology large language model and the Lightning co-pilot work along the process to elucidate the mechanisms of action and molecular targets. Anima’s mRNA Lightning platform is validated by our strategic collaborations with Lilly, Takeda, and AbbVie across therapeutic areas and a pipeline of 20 drug discovery programs.